The BioMed X Institute
6.6.2024 14:57:41 CEST | ACCESS Newswire | Press release
A new research team at XSeed Labs - a collaboration between BioMed X and Boehringer Ingelheim, will develop disease models to understand wound healing and fibrosis.
RIDGEFIELD, CT / ACCESSWIRE / June 5, 2024 / XSeed Labs - a collaboration between BioMed X and Boehringer Ingelheim, announces the start of its first research team on the Boehringer Ingelheim campus in Ridgefield, Connecticut. This research team's main objective is to develop complex, physiologically relevant disease models that deepen our understanding of dysfunctional wound healing and fibrosis. The end goal is to study fibrosis, drug delivery strategies, and drug safety in parallel, in an effort to bridge the gap between research and development to improve patient outcomes accurately and efficiently.
The new research team is led by Dr. Lorenzo Talà, Group Leader at XSeed Labs. "Due to insufficient understanding of the mechanisms driving their pathology, therapies to treat fibrotic diseases are limited. The aim of our research group is to develop physiologically relevant in vitro and in silico fibrosis models. By combining both approaches, we will interrogate disease mechanisms, identify drug delivery pathways, and assess drug safety in order to facilitate drug development toward resolving fibrotic tissues."
Christian Tidona, Founder and Managing Director of the BioMed X Institute: "We are pleased that we could successfully translate the innovation model we established in Heidelberg and New Haven to work inside a major pharma research and development campus. We have a long history of successful collaboration with Boehringer Ingelheim at our Heidelberg institute, and we are proud to extend this collaboration to their U.S. headquarters in Ridgefield, Connecticut."
"We are committed to accelerating innovation across fibrotic diseases. This partnership allows us to harness top talent across the biomedical industry and leverage our leading research and development site in the U.S. to discover insights that could help transform the way we treat these diseases," said Carine Boustany, PhD, U.S. Research Site Head and Global Head of Immunology and Respiratory Diseases Research, Boehringer Ingelheim. "In parallel, we will harness these innovative disease model systems to assess the safety of novel anti-fibrotic concepts, and identify better ways to deliver our molecules," said Xiaorong He, PhD, U.S. Development Site Head and Global Head of Development Sciences, Boehringer Ingelheim.
"We are excited to start our first XSeed Labs team at Boehringer Ingelheim in Ridgefield. It is the beginning of a unique innovation model that promotes scientific exchange between major players in biomedical research," says Mark Johnston, CEO of BioMed X USA.
About BioMed X and XSeed Labs
BioMed X is an independent research institute with sites in Heidelberg, Germany, New Haven, Connecticut, XSeed Labs in Ridgefield, Connecticut, and a worldwide network of partner locations. Together with our partners, we identify big biomedical research challenges and provide creative solutions by combining global crowdsourcing with local incubation of the world's brightest early-career research talents. Each of the highly diverse research teams at BioMed X has access to state-of-the-art research infrastructure and is continuously guided by experienced mentors from academia and industry. At BioMed X, we combine the best of two worlds -- academia and industry -- and enable breakthrough innovation by making biomedical research more efficient, more agile, and more fun.
BioMed X started working with Boehringer Ingelheim in 2015 with a series of joint research projects hosted by the BioMed X Institute in Heidelberg, Germany. The new collaboration model - called XSeed Labs - entails an open innovation incubator embedded in the Boehringer Ingelheim Ridgefield campus in Connecticut, USA.
Contact Information
Flavia-Bianca Cristian
Recruiting & Communications Manager
fbc@bio.mx
+49 6221 426 11 706
Swathi Lingam
Scientific Communication & Editorial Associate
lingam@bio.mx
+49 6221 426 11 27
Related Images
SOURCE: BioMed X Institute & XSeed Labs
To view this piece of content from stats.nwe.io, please give your consent at the top of this page.View the original press release on newswire.com.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
ePropelled to Increase Manufacturing Footprint with $60 Million in U.S. Government Funding to Strengthen U.S. Drone Propulsion Supply Chain11.8.2026 13:00:00 CEST | Press release
Expansion Increases Manufacturing Capacity by 4X and Positions ePropelled as a Leading Domestic Supplier of Advanced Dual-Use Electric Propulsion Systems COVENTRY, UK / ACCESS Newswire / August 11, 2026 / ePropelled, a leading U.S. manufacturer of advanced electric propulsion systems for uncrewed aerial vehicles, aerospace, defense, and commercial applications, today announced a major expansion of its manufacturing operations, increasing its production footprint from 20,000 square feet to 80,000 square feet. The expansion is supported by $60 million in government funding through the Department of War's Industrial Base Analysis and Sustainment program, reinforcing the nation's commitment to strengthening domestic manufacturing of mission-critical drone technologies and advanced dual-use propulsion systems. The expanded facility will increase ePropelled's propulsion system production capacity by more than 4X, enabling the company to meet rapidly growing demand from U.S. government progra
ePropelled to Increase Manufacturing Footprint with $60 Million in U.S. Government Funding to Strengthen U.S. Drone Propulsion Supply Chain11.8.2026 13:00:00 CEST | Press release
Expansion Increases Manufacturing Capacity by 4X and Positions ePropelled as a Leading Domestic Supplier of Advanced Dual-Use Electric Propulsion Systems COVENTRY, UK / ACCESS Newswire / August 11, 2026 / ePropelled, a leading U.S. manufacturer of advanced electric propulsion systems for uncrewed aerial vehicles, aerospace, defense, and commercial applications, today announced a major expansion of its manufacturing operations, increasing its production footprint from 20,000 square feet to 80,000 square feet. The expansion is supported by $60 million in government funding through the Department of War's Industrial Base Analysis and Sustainment program, reinforcing the nation's commitment to strengthening domestic manufacturing of mission-critical drone technologies and advanced dual-use propulsion systems. The expanded facility will increase ePropelled's propulsion system production capacity by more than 4X, enabling the company to meet rapidly growing demand from U.S. government progra
AI/ML Innovations' Subsidiary NeuralCloud Achieves ISO 13485:2016 (MDSAP) Certification11.8.2026 13:00:00 CEST | Press release
Quality Management System Certification Strengthens NeuralCloud's Regulatory Readiness for ECG Software-as-a-Medical-Device Platform TORONTO, ON / ACCESS Newswire / August 11, 2026 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB), a company advancing artificial intelligence and neural-network-based technologies for digital health, is pleased to announce that its wholly owned subsidiary, NeuralCloud Solutions Inc. ("NeuralCloud"), has achieved ISO 13485:2016 certification under the Medical Device Single Audit Program ("MDSAP") for its quality management system. The certification, issued by TÜV USA, Inc., applies to NeuralCloud's quality management system for the design, development, production, and distribution of Software as a Medical Device ("SaMD") for ECG analysis, including advanced PQRST waveform delineation, interval computation, arrhythmia analytics, signal quality scoring, and artifact reporting. ISO 13485 is the internationally recognized qu
RollerAds Launches a Full-Cycle Ad Platform with Traffic, Offers, and Monetization in One Workspace11.8.2026 11:30:00 CEST | Press release
The updated platform unifies campaign management, CPA offers, and website monetization within a single dashboard to help users manage affiliate marketing activities more efficiently from one place. LIMASSOL, CY / ACCESS Newswire / August 11, 2026 / RollerAds announced the official launch of its new full-cycle advertising platform, designed to simplify digital advertising workflows by bringing the entire process into a single workspace. The new platform is now live at my.rollerads.com following several months of open beta testing and product refinement based on user feedback. "Our goal was to make affiliate marketing management simpler and more efficient," said Pierre Bertin, Head of International Business Development at RollerAds. "With the new platform, users can work with campaigns, CPA offers, and monetization tools in one dashboard without switching between multiple accounts or services." One dashboard for the entire advertising workflow The new RollerAds platform allows users to m
Power to Hydrogen Delivers First-of-a-Kind Industrial-Scale AEM Electrolyzer to the Port of Antwerp-Bruges11.8.2026 08:00:00 CEST | Press release
Half-Megawatt System Uses 250-Kilowatt Stacks for Efficient Hydrogen Production At Scale; Installation Now Underway with Commissioning in September ANTWERPEN, BELGIUM / ACCESS Newswire / August 11, 2026 / Power to Hydrogen (P2H2), a developer of anion exchange membrane (AEM) electrolyzer systems, today announced it has delivered and begun installation of a first-of-a-kind half-megawatt AEM electrolyzer at the Port of Antwerp-Bruges in Belgium. The project is the world's first to utilize 250-kilowatt AEM electrolyzer stacks and, once commissioned, will be the first AEM system to demonstrate renewable hydrogen production in a high-throughput industrial port environment under real operating conditions. The milestone marks a major step forward in delivering cost-competitive hydrogen at scale and sets the stage for its public launch, planned for September. The Port of Antwerp-Bruges system is Power to Hydrogen's first commercial deployment of its M-Class hybrid AEM electrolyzers, designed t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom